Larimar Therapeutics shares are trading higher after the company announced that data from its Nomlabofusp Phase 1 studies and Phase 2 dose exploration will be presented at the annual International Congress for Ataxia Research.
Portfolio Pulse from Benzinga Newsdesk
Larimar Therapeutics shares rose following the announcement that data from its Nomlabofusp Phase 1 and Phase 2 studies will be presented at the International Congress for Ataxia Research.
September 19, 2024 | 3:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Larimar Therapeutics' stock price increased after announcing that data from its Nomlabofusp Phase 1 and Phase 2 studies will be presented at a major research congress.
The announcement of presenting study data at a significant research congress is a positive development, likely boosting investor confidence and interest in Larimar Therapeutics, leading to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100